Cabazitaxel for castration-resistant prostate cancer - Authors' reply

The Lancet

Volumn 377, Issue 9760, 2011, Pages 122-123

  De Bono, Johann Sebastian ^a   Sartor, Oliver ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABAZITAXEL; DOCETAXEL; MITOXANTRONE;

CASTRATION; HEART ARREST; HEART VENTRICLE FIBRILLATION; HUMAN; LETTER; MALE; MEDICAL PRACTICE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SUDDEN DEATH;

EID: 79251518068     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60014-7     Document Type: Letter

References (5)

1. AC Mita, LJ Denis, EK Rowinsky Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors Clin Cancer Res 15 2009 723 730
2. G Attard, A Greystoke, S Kaye, J de Bono Update on tubulin binding agents Pathol Biol 54 2006 72 84
3. X Pivot, P Koralewski, JL Hidalgo A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients Ann Oncol 19 2008 1547 1552
4. R Bruno, D Hille, A Riva Population Pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer J Clin Oncol 16 1998 187 196
5. HI Scher, S Halabi, I Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159